Abstract: Chondroitin sulfate (CS) is a ubiquitous component of the cell surface and extracellular matrix of animal tissues. CS chains are covalently bound to a core protein to form a proteoglycan, which is involved in various biological events including cell proliferation, migration, and invasion. Their functions are executed by regulating the activity of bioactive proteins, such as growth factors, morphogens, and cytokines. This review article focuses on the catabolism of CS. This catabolism predominantly occurs in lysosomes to control the activity of CS-proteoglycans. CS chains are fragmented by endo-type glycosidase(s), and the resulting oligosaccharides are then cleaved into monosaccharide moieties from the nonreducing end by exoglycosidases and sulfatases. However, the endo-type glycosidase responsible for the systemic catabolism of CS has not yet been identified. Based on recent advances in studies on hyaluronidases, which were previously considered to be hyaluronan-degrading enzymes, it appears that they recognize CS as their original substrate rather than hyaluronan and acquired hyaluronan-hydrolyzing activity at a relatively late stage of evolution.
INTRODUCTION
Chondroitin sulfate (CS) is a ubiquitous component in extracellular matrices as well as on cell surfaces in animals [1] . CS chains are covalently bound to a core protein to form CS-proteoglycans, which are widely distributed in the animal kingdom from very low organisms such as hydra, planarian, and nematodes to highly developed animals such as vertebrates [2] . The functions of CS-proteoglycans cover a wide range of biological events including cell proliferation, cell differentiation, cell migration, and cell-cell interactions [3] . Some of these activities are executed through interactions with various bioactive components such as growth factors, morphogens, cytokines, and cell adhesion molecules (Fig. 1) . Major CS-binding proteins and some of their related functions and diseases are summarized in Table 1 . CS was previously reported to be indispensable for cytokinesis during early embryonic cell division [4, 5] . It has also been shown to play very important roles in the central nervous system [6, 7] . CS produced mainly by reactive astrocytes after spinal cord injury was identified as the most potent inhibitor of axon regeneration [8] . A previous study demonstrated that the critical period for cortical plasticity was regulated by CS proteoglycans, which determines the maturation of parvalbumin-expressing interneurons [9] . The structure of CS is shown in Fig. 2 . CS is a polysaccharide composed of a simple repeat of the disaccharide unit [-4-D-glucuronic acid (GlcA)1-3-N-acetyl-D-galactosamine (GalNAc)1-] ( Fig. 2A) . CS chains acquire structural variations due to the sulfation of different hydroxyl groups in various combinations, as shown in the figure, leading to the multiple functions of CS [3] . In addition, the C5 position of the GlcA residue can be epimerized to form L-iduronic acid (IdoA). The stereoisomeric variant of CS containing IdoA instead of GlcA residues has been designated as CS-B or dermatan sulfate (DS). Since some of the GlcA residues are replaced by enzymatic epimerization at the polymer level after the polymerization of CS chains, CS and DS are often found in a single polysaccharide chain as a CS-DS hybrid structure. Thus, DS polysaccharide can be considered as a highly modified CS chain at the level of uronic acid. Most of the CS-binding proteins shown in Table 1 appear to interact with CS chains through oligosaccharide domains composed of highly sulfated disaccharides and/or a CS-DS hybrid structure [3] . 
CELLULAR DEGRADATION OF CS
The functions of bioactive molecules are generally regulated in vivo by not only their biosynthesis but also their degradation. The cellular degradation of CS predominantly occurs in lysosomes [10] . However, the catabolic mechanism of CS has not yet been elucidated in detail. In the initial step of CS depolymerization, endo-type hydrolases are considered to fragment CS chains, and the resulting oligosaccharides are then sequentially cleaved from the nonreducing end by exo-type glycosidases and sulfatases to liberate the monosaccharide moieties. These exo-type hydrolases have been extensively investigated because deficiencies lead to a group of hereditary diseases, mucopolysaccharidoses [11] , which belong to lysosomal disorders and are caused by the intracellular accumulation of undegraded CS oligosaccharides. A variety of common symptoms of mucopolysaccharidoses have been reported, including growth retardation, coarsening of facial features, corneal clouding, joint stiffness, and abnormalities in the hands and spine. Although CS is abundantly present in cartilage, it is widely distributed and also exists in the brain. Therefore, progressive neurological dysfunction and mental retardation occur in some types of mucopolysaccharidoses. The lysosomal disorders caused by the lack of CS catabolizing enzymes are shown in Table 2 . Beta-hexosaminidases remove beta-hexosamine residues including beta-GalNAc and beta-GlcNAc from the nonreducing end of oligosaccharides derived from CS, HA, glycolipids, and glycoproteins. The absence of betahexosaminidases affects the catabolism of various glycoconjugates, and neurodegeneration occurs.
The scheme of cellular degradation of CS is shown in Fig. 3 . A representative oligosaccharide sequence is shown as the substrate for exoglycosidases. The non-reducing terminal sugar residue is the first target for the catabolic enzymes because they generally recognize only one non-reducing monosaccharide. In this case, the non-reducing GlcA residue is removed by beta-glucuronidase (Fig. 3,  step 2 ). The newly formed non-reducing terminal GalNAc residue is the next target. If it is sulfated at the C4 or C6 position, the sulfate group is hydrolyzed by GalNAc 4-sulfatase or GalNAc 6-sulfatase, respectively. Since exoglycosidases generally do not degrade substituted sugar residues, such modified groups must first be removed. In this case (Fig. 3, step 3) , the 6-O-sulfate group on the GalNAc residue is removed by GalNAc 6-sulfatase, and beta-hexosaminidase then liberates the non-reducing, unmodified GalNAc residue (Fig. 3, step 4) . As the new non-reducing terminal iduronate residue is sulfated at the C2 position, iduronate 2-sulfatase hydrolyzes the sulfate group (Fig. 3, step 5 ), and alpha-iduronidase then releases the IdoA moiety (Fig. 3, step 6 ). In the next step, the 4-O-sulfate group on the GalNAc residue is removed by GalNAc 4-sulfatase (Fig. 3, step 7 ), and beta-hexosaminidase then cleaves the GalNAc residue (Fig. 3, step 8) . One of the beta-hexosaminidase isozymes, betahexosaminidase A, can remove 4-O-sulfated GalNAc before acting on GalNAc 4-sulfatase (Fig. 3, step 7') [12, 13] . By repeating these hydrolysis steps one by one, CS oligosaccharides are completely depolymerized into GalNAc, uronic acid (GlcA or IdoA), and inorganic sulfate. Since these hydrolases are only able to act on the non-reducing terminal monosaccharide, but not on the internal residues, a deficiency in any one of these exoglycosidases or sulfatases leads to the accumulation of undegraded oligosaccharides and a disorder described as one of the mucopolysaccharidoses. Fig. 3 . Schematic drawing of the cellular degradation of CS. CS degradation is considered to occur in lysosomes. Long CS polymers are fragmented by endo-type enzymes (step 1). The resulting oligosaccharides are then sequentially cleaved from the non-reducing end by exo-type glycosidases as well as sulfatases (steps 2-9). A representative oligosaccharide sequence is shown as the substrate to be completely hydrolyzed. The pertinent target for degradation at each step is underlined. 2S, 4S, or 6S represents 2-O-sulfate, 4-O-sulfate, or 6-O-sulfate, respectively.
ENDOGLYCOSIDASES FOR THE HYDROLYSIS OF CS
The endoglycosidase(s) responsible for the catabolism of CS has not yet been identified. Although hyaluronidases, which were named after their activity to degrade hyaluronan (HA) chains, have been considered to be involved in CS catabolism, their activities toward CS were assumed to be markedly lower than those toward HA [14, 15] . As shown in Fig. 2 , the stereoconfiguration of sugars, the substitution pattern of the backbone hydroxyl groups, and glycosidic bonds are almost identical between CS and HA. The only difference is the steric configuration at the C4 position of the hexosamine residues, except for substitutions with sulfate groups in CS. This structural similarity appears to endow hyaluronidases with the ability to recognize both HA and CS as substrates. There are 6 members in the human hyaluronidase family: hyaluronidase-1 (HYAL1), HYAL2, HYAL3, HYAL4, PH20, and HYALP1 (Table 3) . [16] . The expression of HYAL1 in the brain is very weak [17] , whereas that of KIAA1199 is high, indicating that KIAA1199 may also be responsible for the degradation of HA in the brain. Since KIAA1199 does not recognize CS as a substrate, it does not appear to be the enzyme required for the catabolism of CS. Previous studies suggested that HYAL1 preferentially recognized HA over CS [14, 15] . However, recent quantitative measurements of HYAL1 activity revealed that it hydrolyzed CS and HA at similar velocities [18] . HYAL1 may be the enzyme responsible for the systemic hydrolysis of CS, except for in the brain, because the expression of HYAL1 in the brain is very low, as described above. Although accumulating evidence has indicated the important roles of CS in the development and functions of the brain [6, 7, 9] , the protein(s) required for the catabolism of CS has yet to be identified in this organ.
HYAL2 is also almost ubiquitously expressed, except for in the brain [17] . HYAL2 degrades very large HA chains (Mw = 10 6 -10 7 Da) into smaller HA oligosaccharides (Mw = approx. 20,000 Da or approx. 50 disaccharide units) [19] . The 20 kDa products are further cleaved into oligosaccharides (1,000-2,000 Da) by HYAL1, and then exoglycosidases (beta-glucuronidase and beta-N-acetylhexosaminidase) hydrolyze them from the non-reducing ends [10] . The HA-degrading activity of HYAL2 has only been observed when it is co-expressed with CD44, a receptor for HA [20] . HYAL2-CD44 complex formation may be essential for the hydrolytic activity of HYAL2. Although the CS-degrading activity of HYAL2 has not yet been reported, our preliminary data indicate that HYAL2 can also cleave CS. HYAL3 mRNA is widely expressed in several organs, with high levels being detected in the testis, bone marrow, and prostate [17] . Unequivocal evidence of its enzymatic activity has not yet been presented. Since the accumulation of any glycosaminoglycans was not observed in HYAL3-deficient mice [21] , HYAL3 does not appear to play a major role in the constitutive degradation of HA or CS. HYAL4 has been identified as an enzyme that is specific for CS. Even though it is named as a "hyaluronidase", it hardly acts on HA. The substrate specificity of HYAL4 has been investigated in detail, and its preferred saccharide sequence was identified as -GlcA(2-O-sulfate)-GalNAc(6-O-sulfate)-*GlcA-GalNAc (4-or 6-O-sulfate) (the asterisk indicates the hexosaminidic linkage cleaved by HYAL4) [22] . However, this enzyme does not appear to be the enzyme that systemically catabolizes CS. Its expression is very restricted, and its mRNA has only been detected in the placenta, testis, and skeletal muscle [17, 23] . This enzyme may have specific temporal functions in particular organs and tissues. Strong expression of HYAL4 mRNA has been reported in some tumor cell lines derived from ovarian cancer and cervical cancer, whereas it was not detected in their normal tissues (our unpublished results). HYAL1 has been implicated in cancer proliferation, angiogenesis, and inflammatory diseases, and its expression was found to be up-regulated in the advanced stages of some cancers [24, 25] . Previous studies reported that HA fragments produced by HYAL1 were involved in tumor migration and inflammation [24] . Since some CS oligosaccharides have also been demonstrated to exhibit such biological functions [3, 26] , those generated by HYAL4 may contribute to cancer malignancy. PH-20 is a testicular hyaluronidase that functions during fertilization [27] . The cumulus of the oocyte is enriched with HA, which should be degraded for sperm penetration. PH-20 is a glycosyl phosphatidyl inositol (GPI)-anchored protein that is expressed on the surface of the sperm head after the acrosome reaction [27] . Thus, this enzyme appears to hydrolyze HA in the cumulus of the oocyte and assists sperm to reach the oocyte for fertilization. Although sperm from PH-20-deficient mice showed delayed dispersal of cumulus cells in vitro, male mice lacking PH-20 were fully fertile [28] , suggesting that other hyaluronidase(s) may compensate for the activity of PH-20. Honda et al. quantitatively investigated the hydrolytic activity of PH-20 toward various substrates [18] . Compared to the initial velocity of the digestion of HA, that of CS-A, a CS isomer rich in the GlcA-GalNAc(4-O-sulfate) structure, was higher, whereas that of CS-C, a CS isomer rich in the GlcA-GalNAc(6-O-sulfate) structure, was lower, suggesting that HA was not the best substrate for PH-20 and that the position of sulfation strongly affected substrate recognition by PH-20. HYALP1 is a pseudogene, and its translation product is a truncated and inactive form of the enzyme [17] . The amino acid residues at the active site of HYAL1 and HYAL4 were identified based on a crystal structure analysis [29, 30] and site-directed mutagenesis study [23, 31] . Glu 131 and Tyr 202 in HYAL1 are a likely proton donor for the hydroxyl leaving group and a substrate binding determinant, respectively. Glycosylation on Asn 350 is also necessary for the enzymatic activity of HYAL1. These amino acid residues are conserved in HYAL4 (Glu 147 , Tyr 218 , and Asn 368 , respectively), and mutagenesis of these residues completely eliminated the hydrolytic activity of HYAL4. Although HYAL1 degrades both HA and CS as substrates, HYAL4 was found to exclusively depolymerize CS chains [22, 23] . The only difference in the backbone structure between HA and CS was the hexosamine residue, as shown in Fig. 2 . HYAL4 strictly recognizes the GalNAc residue, whereas HYAL1 tolerates the configuration of the C4 position of the hexosamine residues. Since the amino acid sequences of HYAL1 and HYAL4 are highly similar, the residues responsible for substrate recognition have been investigated. One of the amino acid residues critical for the recognition of this difference has been identified as Tyr 275 in mouse Hyal1, which corresponds to Ser 263 in mouse Hyal4 (our unpublished results). Although hyaluronidases were expected to function in lysosomes due to their acidic optimal pH, HYAL2, HYAL4, and PH-20 do not appear to localize in lysosomes. Since they possess a GPI-anchored domain in the C-terminal region [22, 27, 32] , they can be linked by a GPI anchor to the cell membrane. PH-20 and HYAL4 has been observed at the surfaces of sperm heads [23, 27] , presumably on the acrosomal membrane. The intracellular localization of HYAL2 and HYAL4 has been investigated in an immunofluorescent study, and they were found to be most likely present in early endosomes [23, 33] (our unpublished results). Although the pH in early endosomes as well as cell surfaces is not generally as acidic as pH 4.0-5.0, which is the optimal pH of these hyaluronidases, they may be able to function when tethered to the cell membrane and modulated by other assistant protein(s). The possibility of the existence of other CS-hydrolyzing endoglycosidases with no homology with hyaluronidases cannot be excluded. The isolation of CS/DS oligosaccharides, which have a GlcA residue on their reducing ends, has been reported previously [34] , suggesting that they were generated by digestion with an unidentified endo-beta-glucuronidase, and not by a hyaluronidase-like endobeta-hexosaminidase. Such undiscovered endoglycosidases may also be involved in the systemic catabolism of CS/DS.
SYSTEMIC CATABOLISM OF CS
Since CS exists ubiquitously in mammals, the CS-specific hydrolase HYAL4 does not appear to be involved in the systemic catabolism of CS because of its restricted distribution. Only HYAL1 and HYAL2 mRNAs were found to be ubiquitously expressed among the hyaluronidase family members [17] . The hydrolytic activity of HYAL1 toward CS had previously been considered to be more limited than that toward HA [14, 15] . However, we recently developed a quantitative method to precisely calculate its enzymatic activity, and found that the CS isoform, CS-A, was more effectively hydrolyzed by HYAL1 than HA [18] . HYAL1 may contribute to CS catabolism, except in the brain. Gushulak et al. [35] recently reported the accumulation of CS in HYAL1-deficient mice, suggesting the in vivo functions of HYAL1 in the systemic degradation of CS. Unambiguous evidence of the hydrolytic activity of HYAL2 toward CS has not yet been provided. As described above, the term "hyaluronidase" is a misnomer [19] , because HYAL1 and PH-20 preferentially recognize CS over HA, and HYAL4 only acts on CS. When the GenBank database and other databases were searched, genes homologous to human hyaluronidases were found even in very low organisms, including nematodes [36] and hydra. In contrast, the distribution of HA in the animal kingdom is very restricted (Fig. 4) [2] . Vertebrates mainly synthesize HA, whereas invertebrates do not appear to produce HA; a previous study detected HA in a mollusk bivalve [37] . HA synthase may be obtained at a relatively late stage of evolution. In contrast, CS is widely distributed from very low organisms such as planarians to humans (Fig. 4) , suggesting that CS most likely occurred in evolution prior to HA. Therefore, the genuine substrate of hyaluronidases may be CS rather than HA, and they appear to have later acquired HA-hydrolyzing activity. It is, however, well known that some bacterial strains synthesize polysaccharides with the same backbone structure with HA, chondroitin, and heparan. These glycosaminoglycan polysaccharides are not attached to core proteins and are produced on the inner surface of the cytoplasmic membrane [38] . Thus the origin of the bacterial polysaccharides is most likely different from that of glycosaminoglycans in metazoans. HA in vertebrates appears to arise from chitin, which is widely distributed in invertebrates but not in vertebrates [39] . The mechanism responsible for the systemic catabolism of CS has not yet been completely clarified. However, the involvement of hyaluronidases in CS catabolism has been estimated based on quantitative measurements of their hydrolytic activity toward CS variants in vitro [18] . Mikami et al. [40] reported the involvement of HYAL1 in the degradation of CS at the stage of extensive syncytial myotube formation during muscle development. As described above, the storage of CS in HYAL1-deficient mice was demonstrated previously [34] . Fig. 4 . Distribution of CS and HA in the animal kingdom. The phylogenetic tree of the animal kingdom is depicted. Representative animals in which the glycosaminoglycan structure has been characterized are shown in parentheses. DS is a CS isoform that contains IdoA instead of GlcA in CS. HA is almost exclusively distributed in vertebrates, but was also previously detected in a bivalve mollusk [37] . Neither CS nor HA has been found in Porifera.
Evidence for the involvement of hyaluronidases in the in vivo degradation of CS is accumulating. However, many issues still need to be solved, including how CS chains are catabolized in the brain, whether an endo-glucuronidase specific for CS/DS exists, what the in vivo function of the CS-specific HYAL4 is, whether HYAL3 has any enzymatic activity toward glycosaminoglycans, how the GPI-anchored but acid-active hyaluronidases HYAL2, HYAL4, and PH20 act at the cell surface or in the extracellular matrix, and why HYAL1-or HYAL2-deficient mice exhibit less severe phenotypes than those of mice deficient in exo-type CS/HA glycosidases. Future studies will provide the answers to these questions. 
